Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
53 hedge funds and large institutions have $19.7M invested in Kronos Bio in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1.68% less ownership
Funds ownership: 34.36% → 32.68% (-1.7%)
5% less funds holding
Funds holding: 56 → 53 (-3)
23% less capital invested
Capital invested by funds: $25.6M → $19.7M (-$5.86M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$343K |
| 2 |
Renaissance Technologies
New York
|
+$238K |
| 3 |
Millennium Management
New York
|
+$208K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$123K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$82.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
-$1.29M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.05M |
| 3 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$342K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$156K |
| 5 |
Jane Street
New York
|
-$96.3K |
KRON Hedge Fund Activity: Q3 2024 in Review
53 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q3 2024, worth a combined $19.7M — down 23% from $25.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KRON and 7 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $343K. The largest seller was Mariner, exiting entirely with an estimated $1.29M sold.
- 53 institutional investors held Kronos Bio (KRON) as of Q3 2024, down from 56 in Q2 2024.
- Funds reported $19.7M of Kronos Bio stock for Q3 2024, down 23% quarter-over-quarter.
- 7 funds opened new Kronos Bio positions in Q3 2024 and 10 closed out, a net change of -3 holders.
- The largest Kronos Bio buyer in Q3 2024 was Woodline Partners, an estimated $343K added.
- The largest Kronos Bio seller in Q3 2024 was Mariner, an estimated $1.29M sold.
Based on aggregated 13F filings for Q3 2024.